We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in Oncology

Journal Scan / Research · February 25, 2023

Novel Salvage Regimens vs Conventional Chemotherapy Before ASCT in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma

American Journal of Hematology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Charles Gaulin MBBS

American Journal of Hematology
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
Am. J. Hematol 2023 Jan 11;[EPub Ahead of Print], SH Desai, MA Spinner, K David, V Bachanova, G Goyal, B Kahl, K Dorritie, J Azzi, VP Kenkre, S Arai, C Chang, B Fusco, N Sumransub, H Hatic, R Saba, U Ibrahim, EI Harris, H Shah, J Murphy, S Ansell, D Jagadish, V Orellana-Noia, C Diefenbach, S Iyenger, KC Rappazzo, R Mishra, Y Choi, GS Nowakowski, RH Advani, IN Micallef

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated